0 Persons are tagged with #antibodies

#antibodies

One person like that
2 Likes
1 Shares
digit@joindiaspora.com
Digit

while reading

https://scitechdaily.com/inescapable-covid-19-antibody-discovery-neutralizes-all-known-sars-cov-2-strains/

a couple phrases evoked a couple thoughts...

including newly emerged mutants

newly emerged

yeah, oh really? but:
https://odysee.com/@devrijeomroep:6/covid-patent-gate:2
( as i posted here: https://joindiaspora.com/posts/1f5f9e30e40c0139e181002590d8e506 / https://dnext.societas.online/posts/1f5f9e30e40c0139e181002590d8e506 )

closely related

"closely related" :3 :3 :3

as nice as some of this "news" (marketing) is, it's still worth holding in broader context, remembering the matroska boxes these narratives are still in.

Sotrovimab, the newest antibody therapy, was developed by GlaxoSmithKline and Vir Biotechnology after a large collaborative study by scientists from across the nation discovered a natural antibody (in the blood of a SARS survivor, back in 2003) that has remarkable breadth and efficacy.

Experiments showed that this antibody, called S309, neutralizes all known SARS-CoV-2 strains – including newly emerged mutants that can now “escape” from previous antibody therapies – as well as the closely related original SARS-CoV virus.

so... we'll be done with this for-profit&control corporate/fascist terror scam episode now, hrmm? XD

and again, that just further reminds me of that leaked line from yyyyyears ago from some middling insider that went a little something like this: "when the terrorist thing wears off, we're going to have people running scared of a disease without symptoms."

#covid #scamdemic #plandemic #antibodies #sars #biotech #bigpharma #health #publichealth #society #hijackingsociety #biggestwealthtransferever

"there are no new variants" "all the patents are fraudulent"

and since that [patentgate [& natural antibodies already found]] info's out, they seem to doubt their ability to maintain this scam, and seem scrambling for their backup escape narratives. ... makes me wonder what next they have planned already... since 9-11'd been planned since, idk, when were the earliest depictions of that in cinema? 1970s? and covid seems planned since at least the 1990s. ... what's next, and how long's it been in the planning? cos the old dominator oligarchy clubs are not gonna stop... not gonna be suddenly as nice and caring as they attempt preen themselves to appear.

also, reminds of one of those two lines i point out in relation to "spaceships for everybody", "anything you can imagine, we already know how to do.", and evokes wonder at what else, suppressed, held onto, for these ploys of power imbalances.

“Inescapable” COVID-19 Antibody Discovery – Neutralizes All Known SARS-CoV-2 Strains

An antibody therapy that appears to neutralize all known SARS-CoV-2 strains, and other coronaviruses, was developed with a little help from structural biologist Jay Nix. Lifesaving COVID-19 vaccines are allowing us to feel optimistic again, after...

One person like that
3 Comments
hylascall@nerdpol.ch
hylascall

Game gets easier and easier

#covid #vaccines #experimentation #antibodies #effectiness #misleading-data

"Dopo Pfizer che ha pubblicato i dati a sei mesi del proprio vaccino, ricavandoli con apprezzabile impegno da quanto ancora il suo originario studio clinico ora in disarmo era in grado di dire, arriva Moderna che sulla prestigiosa rivista Science propone un approccio radicalmente differente e alquanto originale per i suoi dati a sei mesi.
I dati pubblicati infatti non riguardano più l'efficacia dei vaccini sullo sviluppo di covid o su altri aspetti di diretto rilievo clinico, bensì la persistenza in circolo di anticorpi contro le diverse varianti del virus.
Dal punto di vista aziendale l'approccio è molto conveniente in quanto permette di evitare di condurre studi su decine di migliaia di persone, come uno studio di efficacia clinica imporrebbe. Nel presente lavoro tutte le analisi sono state condotte su 24 persone, 8 per fascia d'età. L'idea alla base dello studio è ovviamente che la presenza di anticorpi sia predittiva di una determinata protezione.
A oggi tuttavia non vi è alcuna evidenza che un determinato profilo anticorpale possa avere un qualsivoglia significati rispetto ai rischi del covid. Coerentemente, la presenza di anticorpi in un qualsiasi individuo è considerata indicazione di un passato covid o di una passata vaccinazione, ma non esistono livelli qualitativi o quantitativi utili a riconoscere l'esistenza di una protezione. E probabilmente non esisteranno mai.
In altri termini, mentre dal punto di vista dell'industria vedersi riconoscere la validità della presenza di anticorpi come surrogato della protezione contro il covid rappresenta un'attraente prospettiva che le semplificherebbe enormemente la vita per questi come per futuri vaccini, dal punto di vista dei sistemi sanitari e dei cittadini un dato del genere non sposta di nulla "gli equilibri", poichè quello che serve in concreto per comprendere se e quanto un vaccino possa essere utile è documentarne la capacità di ridurre contagi, malattie, ricoveri e decessi.
Ma per ottenere queste informazioni sono indispensabili quegli studi difficili, lungi e costosi che tutte le aziende si sono affrettate ad abbandonare (con le migliori motivazioni etiche) una volta incassate le autorizzazioni in emergenza. E non bastano certo le affannose raccolte di dati osservazionali dal mondo reale che le istituzioni si affannano a condurre.
Così, il riscontro di tassi anticorpali apprezzabili in un paio di dozzine di persone sono al massimo delle belle lucciole che brillano nel cielo notturno di un'autorevolissima rivista scientifica, ma per uscire dal buio del tunnel servono come minimo delle potenti lanterne, che solo studi clinici ben progettati e appropriatamente condotti ci potranno fornire. E se si continua a insistere su una sola strategia monocorde non è nemmeno detto che bastino. "

Dott. Marco Cosentino

"After Pfizer, which has published the data of six months of its vaccine, obtained with appreciable effort from what its original clinical study now in disarmament was still able to say, comes Moderna in the prestigious journal Science proposes a radically different approach and quite original for its data to six months.
The published data no longer concern the effectiveness of vaccines on the development of covid or on other aspects of direct clinical importance, but the persistence in circulation of antibodies against the different variants of the virus.
From a business point of view the approach is very convenient as it allows you to avoid conducting studies on tens of thousands of people, as a clinical efficacy study would require. In the present study, all analyses were conducted on 24 people, 8 by age group. The idea behind the study is obviously that the presence of antibodies is predictive of a certain protection.
To date, however, there is no evidence that a given antibody profile can have any significance in relation to the risks of covid. Consistently, the presence of antibodies in any individual is considered an indication of a past covid or a past vaccination, but there are no qualitative or quantitative levels useful to recognize the existence of protection. And they probably never exist.
In other words, while from the point of view of the industry to be recognized the validity of the presence of antibodies as a surrogate of protection against the covid represents an attractive perspective that would simplify greatly the life for these as for future vaccines, from the point of view of health systems and of the citizens of a given gender not move anything "the balance", as the one who serves in practice to understand if and how a vaccine might be useful is to document the ability to reduce infections, illnesses, hospitalizations, and deaths.
But to obtain this information are indispensable those difficult, long and expensive studies that all companies have rushed to abandon (with the best ethical reasons) once they have collected emergency authorizations. And the hard-working collections of observational data from the real world that institutions are struggling to conduct are certainly not enough.
Thus, the finding of appreciable antibody rates in a couple of dozen people are at most beautiful fireflies shining in the night sky of a very authoritative scientific journal, but to get out of the darkness of the tunnel serve as a minimum of powerful lanterns, which only well-designed and properly conducted clinical studies will be able to provide us with. And if we continue to insist on a single one-way strategy, it is not even said that they will suffice. Dr. Marco Cosentino

Marco Cosentino, PhD in Pharmacology and Toxicology, as well as full professor of Pharmacology at the School of Medicine of the University of Insubria, where he directs the Research Center in Medical Pharmacology. Professor Cosentino is also the author of hundreds of publications in international journals, books and book chapters, concerning the pathophysiology and pharmacotherapy of diseases of the nervous and immune systems, clinical pharmacology, pharmacogenetics and pharmacovigilance.

One person like that
2 Likes
3 Comments